

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**LIPPO LIMITED**

力寶有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 226)**

**LIPPO CHINA RESOURCES LIMITED**

力寶華潤有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 156)**

## **JOINT ANNOUNCEMENT**

### **INSIDE INFORMATION**

#### **UPDATE ON THE EXIT OFFER FOR THE PROPOSED VOLUNTARY DELISTING OF HEALTHWAY MEDICAL CORPORATION LIMITED**

Reference is made to the joint announcements issued by Lippo and LCR dated 3 July 2023, 29 September 2023 and 16 October 2023 (the “**Announcements**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meaning as defined in the Announcements.

This joint announcement is made pursuant to rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined in the Listing Rules).

The respective Boards of Lippo and LCR wish to update their respective shareholders and potential investors on the further developments in relation to the Delisting and Exit Offer.

Oversea-Chinese Banking Corporation Limited (“**OCBC**”), for and on behalf of the Offeror, announced on 26 October 2023 that the Exit Offer had closed at 5:30 p.m. (Singapore time) on 26 October 2023. Based on information available to the Offeror, as at 5:30 p.m. (Singapore time) on 26 October 2023, the Offeror and parties acting in concert with it (which includes the LCR Group) owned, controlled or have agreed to acquire (including by way of valid acceptances of the Exit Offer) an aggregate of 3,108,353,728 Healthway Shares, representing approximately 68.53% of the total number of issued Healthway Shares. Healthway also announced on 27 October 2023 that it had requested the SGX-ST to suspend the trading of Healthway Shares with effect from 9:00 a.m. (Singapore time) on 27 October 2023.

For more details on the latest update on the Delisting and the Exit Offer, please refer to the announcements made by Healthway and OCBC, for and on behalf of the Offeror, posted on the website of each of the SGX-ST (at [www.sgx.com](http://www.sgx.com)) and Healthway.

**Shareholders and potential investors of each of Lippo and LCR are advised to exercise caution when dealing in the shares of each of Lippo and LCR.**

By Order of the Board  
**LIPPO LIMITED**  
**John Luen Wai Lee**  
*Managing Director and  
Chief Executive Officer*

By Order of the Board  
**LIPPO CHINA RESOURCES LIMITED**  
**John Luen Wai Lee**  
*Chief Executive Officer*

Hong Kong, 27 October 2023

As at the date of this announcement, the board composition of each of Lippo and LCR is as follows:

**Lippo**

*Executive Directors:*

Dr. Stephen Riady (*Chairman*)  
Mr. John Luen Wai Lee  
*(Managing Director and  
Chief Executive Officer)*  
Mr. Brian Riady

*Non-executive Directors:*

Mr. Jark Pui Lee  
Mr. Leon Nim Leung Chan

*Independent Non-executive Directors:*

Mr. King Fai Tsui  
Mr. Victor Ha Kuk Yung  
Ms. Min Yen Goh

**LCR**

*Executive Directors:*

Dr. Stephen Riady (*Chairman*)  
Mr. John Luen Wai Lee  
*(Chief Executive Officer)*  
Mr. James Siu Lung Lee  
Mr. Brian Riady

*Non-executive Director:*

Mr. Leon Nim Leung Chan

*Independent Non-executive Directors:*

Mr. Edwin Neo  
Mr. Victor Ha Kuk Yung  
Ms. Min Yen Goh